This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Heart Outcomes Prevention Evaluation Study

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Original HOPE study (1):

  • designed to investigate the effects of taking an ACE inhibitor ramipril and/or vitamin E for at least 4 years, on a wide range of vascular endpoints

  • total of 9541 patients (men and women) older than 55 years took part in study

  • patients were included if they were at high risk of cardiovascular events due to history of diabetes, previous ischaemic heart disease, peripheral vascular disease or stroke

  • treatment benefits of ramipril were seen across all patient groups - these benefits occurred within 3 to 4 months of starting treatment with ramipril

  • results revealed that the combined reduction in myocardial infarction, cardiovascular death and stroke at 5 years was 22 % in the ramipril treatment group; there was a 17% reduction in all cause mortality in the ramipril treatment group; no effect on stated endpoints occurred with patients treated with vitamin E

  • the study investigators do not attribute treatment benefits accrued with ramipril to be because of an impact on blood pressure - the baseline blood pressure had a mean level of 139/79 mmHg - by the end of the trial there had only been a small further decline

HOPE follow-up study (2):

  • a follow-up study based on the HOPE study population has been undertaken
    • 4,528 patients agreed to further follow-up (median follow-up period 2.6 years)
      • rates of use of angiotensin-converting-enzyme inhibitors (ACEIs) in the 2 groups (72% ramipril versus 68% placebo) were similar after the end of the trial
      • during the post-trial follow-up, patients allocated to ramipril had a 19% further lower relative risk (RR) of myocardial infarction (MI), a 16% lower RR of revascularization, and a 34% lower RR of a new diagnosis of diabetes
        • RR reductions in vascular events were observed during and after the active phase of the trial, regardless of baseline risk (RR of 0.76, 0.89, and 0.83 for low-, medium-, and high-risk patients, respectively) or ancillary treatments (RR of 0.90 for aspirin, 0.76 for beta-blockers, and 0.84 for lipid-lowering medication)
    • the study authors noted that the benefits of ramipril observed during the active period of the HOPE trial were maintained during post-trial follow-up for cardiovascular death, stroke, and hospitalisation for heart failure
      • additional reductions in MI, revascularization, and the development of diabetes were observed during the follow-up phase despite similar rates ACEI use in the 2 randomized groups
      • benefits associated with ACEI use were consistent regardless of patient risk or ancillary treatments
      • the benefits observed in the study extension data indicate that the 4.5 years of initial, "earlier" use of ramipril therapy provided a longer-term protective effect compared with later initiation
      • during the follow-up period, there was not observed an additional treatment effect for stroke
        • blood pressure was similar during the post-trial follow-up and suggests that an important mechanism by which strokes may have been reduced during the blinded part of the study (where there was a modest difference in blood pressure of 3/2 mm Hg) was blood pressure lowering
      • the study authors concluded that ACE inhibitor therapy should be used in most patients with vascular disease or diabetes and additional CV risk factors

Vitamin E in the prevention of cardiovascular disease:

  • study evidence (1,3) has provided no evidence of benefit of vitamin E supplementation in the prevention of the development cardiovascular disease

Vitamin C supplementation in the prevention of cardiovascular disease:

  • in a large, long-term trial of male physicians, neither vitamin E nor vitamin C supplementation reduced the risk of major cardiovascular events (3)

Homocysteine lowering therapy and stroke risk (4)

  • HOPE 2 investigators have analyzed stroke outcomes among participants of the HOPE 2 trial that randomized 5522 adults with known cardiovascular disease to a daily combination of 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12, or matching placebo, for 5 years
    • among 5522 participants, stroke occurred in 258 (4.7%) individuals during a mean of 5 years of follow-up. The geometric mean homocysteine concentration decreased by 2.2 micromol/L in the vitamin therapy group and increased by 0.80 micromol/L in the placebo group
    • the incidence rate of stroke was 0.88 per 100 person-years in the vitamin therapy group and 1.15 per 100 person-years in the placebo group - the hazard ratio [HR], 0.75; 95% (CI, 0.59-0.97) was significant
    • vitamin therapy also significantly reduced the risk of nonfatal stroke (HR, 0.72; 95% CI, 0.54-0.95) but did not impact on neurological deficit at 24 hours (P=0.45) or functional dependence at discharge or at 7 days (OR, 0.95; 95% CI, 0.57-1.56)
    • this study data suggests that homocysteine lowering therapy may have a role in lowering stroke risk
    • a meta-analysis has suggested that folic acid reduces risk of stroke (5)

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.